The disease control rate (DCR) was 61.5% in 13 patients with PIK3CA-mutated endometrial cancer, 80.0% in five patients with AKT-altered endometrial cancer and 37.5% in 16 patients with ovarian clear cell carcinoma. This evidence concerns the gene PIK3CA and ovarian clear cell cancer.